RT Journal Article SR Electronic T1 Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6511 OP 6513 VO 36 IS 12 A1 JEROME H. CHECK A1 DIANE CHECK A1 CARRIE WILSON A1 PATRICE LOFBERG YR 2016 UL http://ar.iiarjournals.org/content/36/12/6511.abstract AB Case Report: We show long-term high-quality survival following single-agent treatment with a progesterone receptor antagonist in two cases of advanced metastatic cancer. Because no biopsy was performed (patient refused) the exact type of lung cancer was not determined but the majority of oncologists who evaluated the patient thought that the rapid onset and syndrome of inappropriate anti-diuretic hormone was more consistent with small-cell lung cancer. The US Food and Drug Association granted a compassionate-use investigational new drug approval for use of single-agent 200 mg mifepristone orally/day to a moribund woman with never-treated metastatic lung cancer and a male with bilateral renal cell carcinoma who had undergone only a unilateral hemi-nephrectomy. Both had long-term high-quality survival (5 years for the patient with lung cancer with complete remission of all lung lesions, and 12 years for the male patient with kidney cancer). Neither patient had any side-effects from mifepristone therapy. Conclusion: These cases helped influence the US Food and Drug Association in granting an investigator-initiated investigational new drug study on advanced non-small cell lung cancer.